Key Points . . . ➤ The peripheral nervous system is comprised of three functional divisions: autonomic, motor, and sensory. ➤ Peripheral neuropathy is a dose-limiting toxicity of cisplatin, paclitaxel, and vincristine and commonly is associated with oxaliplatin and bortezomib. ➤ Baseline and continued assessment are imperative for early diagnosis. ➤ Anticonvulsants and antidepressants are the mainstay of treatment for neuropathic pain.
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n 1987, Holden and Felde noted that "much of the difficulty educating individuals about peripheral neuropathy arises as a result of lack of knowledge on the parts of physicians and nurses " (p. 13). This still is true today. The nervous system has not been the focus of education or training for oncology nurses. As a consequence, their comfort and ability to educate patients have been limited. Recent improvements in the management of other treatment-related toxicities have led to peripheral neuropathy becoming a dose-limiting toxicity of three commonly used chemotherapeutic groups, particularly platinols, vinca alkaloids, and taxanes. This recognition has made peripheral neuropathy an important component in the care of patients with cancer.
